An old Asian saying alve replacement continues to be the most V/ important advance in the treatment of patients with symptomatic, severe valvular heart disease; however, the major problem has been the complications. [1] [2] [3] Mitral valve repair for mitral regurgitation was performed 30 years ago by Lillehei et al, 4 Merendino and Bruce,5 Kay et al, 6 Scott et al, 7 Guidry et al, 8 and McGoon9 and in the 1960s by others. Kay et al'0 have advocated and practiced mitral valve repair for mitral regurgitation for the past 30 years. In the 1970s, the elegant and sophisticated methods of mitral valve repair of Carpentier,"11'2 as well as those of Duran and Ubago,13 have provided the needed thrust for its greater use.
It is our hope that mitral valve repair that does not involve implanting prosthetic material will be associated with a lower complication rate and a better survival than that seen with valve replacement; it is supported by studies that show a lower operative mortality, lower incidence of thromboembolism, a better long-term survival, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] and improved left ventricular function.25,26 However, it is possible that valve function after mitral valve repair is not different from that seen after valve replacement27 and that mitral valve repair may at times produce left ventricular outflow obstruction.28 As we review the results of mitral valve repair, it is appropriate to reflect on some of the lessons already learned from the results of valve surgery to avoid the same pitfalls.
Historical Perspective In 1974, McGoon29 pointed out that comparison and evaluation of various prostheses had occurred by a process of trial and error and advocated "a more systematized process of innovation and evaluation, whereby the well-being of our patients can be more certainly protected." He pointed out that comparisons of prostheses must be made between groups of patients with similar preoperative risk factors and intraoperative care because a randomized clinical trial was impractical. In 1975,1 it was emphasized that before a valid comparison of various prostheses can be made, it is important that we know that the condition of patients who receive the different devices is identical or at least similar; a view that was reiterated in 1983.3 Such a situation may be obtained by a properly designed and conducted prospective, randomized clinical trial or a prospective, well-controlled study.' This led to the formulation and performance of the Veterans Administration's cooperative randomized clinical trial .30 In 1977, the Stanford group demonstrated that patient-related risk factors were predictors of the results of isolated mitral valve replacement.3' In 1980, Macmanus et a132 and Teply et al33 demonstrated that patients operated on in the more recent time period had better results. In 1984, Turina and coworkers34 demonstrated that patients operated on for aortic regurgitation in [1975] [1976] [1977] [1978] [1979] had a better 5-year survival than those who had surgery in [1970] [1971] [1972] [1973] [1974] because of a significantly better clinical condition and ventricular function of the patients.
The "time factor," that is, time as a variable, includes differences in the clinical condition, ventricular function, and cardiovascular function of patients; in medical treatment; in operative techniques; and in preoperative and postoperative care. Its importance is not uniquely related to valve surgery. For example, it also applies to patients with coronary artery disease treated with or without interventional therapy. 35 Notwithstanding all of the above, in the 1970s and 1980s, many nonrandomized and uncontrolled studies continued to claim to show similar or even better results with one valve replacement device or other or with valve repair as opposed to valve replacement. These were inappropriate conclusions.
Problems With Analytic Comparisons of Results of Valve Replacement From Different Time Periods or Different Centers
It is well recognized that nonrandomized comparisons, and even randomized trails, are beset with a multitude of pitfalls in evaluating the results of coronary bypass surgery. [35] [36] [37] In principle, these problems also apply to evaluating results of surgery for valve disease; two experiences serve to illustrate the difficulties involved. Data from Stanford University indicated that there were no significant differences between patients who received the Starr-Edwards valve and patients who received the porcine bioprosthesis; seven patient characteristics had been analyzed. Therefore, they concluded that their data could be used to compare the results with use of the two prostheses and that their results with the Starr-Edwards prostheses that were implanted between 1968 and 1975 could be used for analytical comparisons with results using other prostheses at different time periods or different centers. 38, 39 The problems with such a position are found in ignoring various important features such as the time factor, prospective versus retrospective data collection, completeness and accuracy of relevant data, physician and research assistant bias, some complications that are related to physicians and patients rather than prosthesis, and exclusion of certain valve-related complications40; these issues were rejected by Miller.4' Less than 2 years later, better analyses of the same data by Mitchell et a142 clearly demonstrated that the valve-related complications were more importantly related to patient-related factors than to the type of prosthesis that was used. It is of interest that in 1984, the Stanford group ignored what they had shown in 1977, namely, that patient-related factors were important determinants of valve replacement.3' In another example, a study by Calderwood et a143 did not show that previous infective endocarditis was a risk factor for prosthetic valve endocarditis probably because previous endocarditis was not entered into the data analysis. These examples also illustrate that multivariate and other complex statistical analyses are "not standardized techniques and contain artistic as well as scientific components""4; they can vary from center to center and even within the same center.
It should be reemphasized that computers, complex statistical adjustments, and multivariate analyses will not necessarily provide the correct or accurate solution to errors of study design and of other methodological problems.36
Determinants of the Results of Valve Replacement
Two prospective randomized clinical trials (the Edinburgh and the Veterans Administration's cooperative studies)30 45 that compared a mechanical prosthetic valve with a bioprosthetic valve have shown that up to 7 years after surgery there were no significant differences in the results with regard to survival, reoperation, and valve-related complications ( Table 1 ). The conclusion is that factors other than the type of prosthesis evaluated were more important in determining the intermediate (5-7 years) results of valve replacement. Both trials failed to confirm that thromboembolism was a greater haz- ard with mechanical valves than with bioprosthetic valves, probably because the risks of systemic embolism in patients with valvular heart disease are multifactorial ( Table 2 ); the major difference was the incidence of anticoagulation-related bleeding. In the Veterans Administration's study, the incidence of anticoagulation-related bleeding was 4-5%/yr; on the other hand, the Edinburgh Study reported that complications of bleeding were rare and that of anticoagulation was 1-1.5%/yr. The precise cause(s) for these differences is not clear; however, the recommended level of anticoagulation in the Veterans Administration's study was a prothrombin time two to two and one half times the control value, a value that is much higher than is generally recommended in patients with prosthetic heart valves46-48 and that may account for some of the observed difference. In patients with prosthetic heart valves, prothrombin time should be kept between 1.6 and 1.9 times the control value46; protimes higher than two are associated with a significantly higher incidence of bleeding47,48 but without a further reduction in the incidence of thromboembolism. Other differences between the studies, such as patientrelated factors and health care delivery factors, probably account for most of the observed differences between the two trials.
Unexpectedly, the Veterans Administration's cooperative study failed to show a clinically meaningful or statistically significant difference in the hemodynamics of various commonly used sizes of a tilting-disc mechanical and bioprosthetic valves. 49 Effects of valve replacement on hemodynamics and left ventricular function were also shown to be related to patient-related factors. 50 Certain complications, for example, mechanical failure, degeneration, thrombosis, and need for anticoagulation, vary with different prostheses,51 and, thus, the type of prosthesis also influences the results of valve surgery.
Health care delivery factors are other important determinants of the results of valve surgery (Table  3 ). These factors are multiple, complex, and interrelated. Some (i.e., early diagnosis and proper treatment of complication of prosthetic valves and specialized care with anticoagulant medications) are uniquely related to valve disease. Do These Considerations Also Apply to Valve Repair?
Data from India of closed mitral commissurotomy (repair) for mitral stenosis indicate a 25-year survival of 84%,52 whereas those from the United States indicate a 20-year survival of only 20-50%. 53 The likely reason for this large difference in survival is the different clinical and disease characteristics of the operated patients.
The studies that have compared mitral valve repair to mitral valve replacement are retrospective, uncontrolled studies that have preselected patients for repair on the basis of pathological and etiological factors. Preoperative clinical and functional state of patients undergoing repair was much better; moreover, at follow-up in many subgroups, a small number of patients were at risk.14-24 Of importance, data from studies by Kirklin22 and Sand et a123 indicate that the better survival of patients undergoing valve repair when compared with those undergoing valve replacement for mitral regurgitation was not significant when differences in baseline patient characteristics were retrospectively taken into account. Thus, the considerations that relate to valve replacement (Table 1) will also apply to mitral valve repair.
In a recent editorial in Circulation, Galloway et a154 have suggested that mitral valve repair, using a variety of techniques or their combination, was possible and should be undertaken in the majority of patients who need surgery for mitral regurgitation. Thus, the current clinical practice is to increasingly recommend valve repair in those who are suitable for valve repair and valve replacement in the others. Can the results from these two groups be subsequently compared? Even in the same time period, at even the same medical center, it may not be appropriate to compare the results of valve repair with valve replacement unless the patients treated by the two methods are virtually identical. To reiterate, such a situation may be obtained by a properly designed and conducted prospective, randomized clinical trial or a prospective, well-controlled study.'
Conclusions
An important lesson was learned over the past two decades, namely, the results of valve surgery are dependent on many factors (Table 1) ; the type of surgery or valve replacement device is only one variable that influences the results. It is our hope that the results of valve repair, particularly with regard to complications, will be superior to that of valve replacement. However, there is a need for well-controlled studies documenting these results that would enable us to more certainly protect the well-being of our patients.
